Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

The Trust Test

icons related to iconography inside Cuttsy+Cuttsy branded shapes

Clinical trials explained: Why iconography matters…

Icons serve as a useful form of alternative communication. We spend a lot of time developing icons for healthcare communications. Find out how we use iconography to elevate clinical trial...

Cuttsy + Cuttsy

- PMLiVE

Bringing omnichannel to medical affairs: what do you need to know?

By Frank Fisher

Amiculum

- PMLiVE

MHRA approves Santhera’s Duchenne muscular dystrophy drug Agamree

The rare muscle-wasting disorder is estimated to affect one in 3,500 male births worldwide

Bayer symbol

Bayer’s non-hormonal menopause drug elinzanetant shows promise in phase 3 studies

Vasomotor symptoms are estimated to affect up to 80% of menopausal women

- PMLiVE

Study reveals Takotsubo syndrome patients failed by current cardiovascular treatments

Takotsubo syndrome patients were found to be as vulnerable to dying as heart attack patients

Trends in Virtual Collaboration

Join us for a look at the top-5 emerging virtual collaboration trends...

Impetus Digital

- PMLiVE

Stirred announces Stirred Well, a new wellness offering

The move will extend the agency’s reach into the preventative, everyday health space

Unlock possibilities: A Medical Affairs strategy fit for the future

Explore the key areas to include in a Medical Affairs strategy and plan that is fit for the future in our latest whitepaper.

OPEN Health

- PMLiVE

GSK to expand respiratory pipeline with $1.4bn Aiolos Bio acquisition

The deal includes a monoclonal antibody ready to enter phase 2 development for asthma

- PMLiVE

Dermavant reports positive phase 3 results for Vtama cream in atopic dermatitis

More than 26 million people in the US are affected by the inflammatory skin disease

- PMLiVE

Merck granted FDA approval for Keytruda combination in cervical cancer

The decision marks the third FDA-approved indication for Keytruda in cervical cancer

- PMLiVE

Pfizer’s COVID-19 antiviral Paxlovid recommended by NICE for expanded use

The latest guidance will mean an estimated 5.3 million people will be eligible to access Paxlovid

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links